BIM 23190

Also Known As:

BIM-23190; N-(N'-(2-hydroxyethyl)-piperazinyl)-2-acetyl-Phe-Cys-Tyr-Trp-Lys-Abu-Cys-Thr-NH2 disulfide; N-(N'-(2-hydroxyethyl)piperazinyl)-2-acetyl-phenylalanyl-cysteinyl-tyrosyl-tryptophyl-lysyl-2-aminobutanoyl-cysteinyl-threoninamide disulfide

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Oligopeptides: 519
    - BIM 23190: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - BIM 23190: 3

Experts

1.	Aiello, Cinzia: 1 article (11/2009)
2.	Bajetto, Adriana: 1 article (11/2009)
3.	Barbieri, Federica: 1 article (11/2009)
4.	Culler, Michael D: 1 article (11/2009)
5.	Ferrari, Angelo: 1 article (11/2009)
6.	Florio, Tullio: 1 article (11/2009)
7.	Gatti, Monica: 1 article (11/2009)
8.	Lunardi, Gianluigi: 1 article (11/2009)
9.	Pattarozzi, Alessandra: 1 article (11/2009)
10.	Quintero, Ana: 1 article (11/2009)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2001 - "SST-14 inhibited GH secretion in 8 of 13 tumors; lanreotide, BIM-23190, and BIM-23268 inhibited GH secretion in six tumors each (range of GH secretion inhibition 23-43%; median 33%). " 07/01/2001 - "Our results showed that cell proliferation was significantly inhibited by SST-14, lanreotide, BIM-23190, and BIM-23268 in 4, 7, 3, and 4 tumors, respectively (range of proliferation suppression 5-60%; median, 16%). " 04/01/1998 - "Based on higher plasma levels, greater distribution to target tissues and longer in vivo stability, BIM-23190 and BIM-23197 may prove to be superior to BIM-23014 for the treatment of acromegaly and some types of cancer."
2.	Pituitary Neoplasms (Pituitary Adenoma) 07/01/2001 - "We investigated the effects of SST-14, lanreotide, and SSTR 2 (BIM-23190) and SSTR 5 (BIM-23268) specific analogs in 18 somatotroph pituitary adenomas in primary culture. "
3.	Glioma (Gliomas) 11/01/2009 - "In C6 rat glioma cells, somatostatin is cytostatic in vitro via phosphotyrosine phosphatase-dependent inhibition of ERK1/2 activity mediated by SSTR1, -2, and -5. Here we analyzed the effects of SSTR activation on C6 glioma growth in vivo and the intracellular mechanisms involved, comparing somatostatin effects with selective agonists for SSTR1, -2, and -5 (BIM-23745, BIM-23120, BIM-23206) or receptor biselective compounds (SSTR1 and -2, BIM-23704; and SSTR2 and -5, BIM-23190). "
4.	Acromegaly 04/01/1998 - "Based on higher plasma levels, greater distribution to target tissues and longer in vivo stability, BIM-23190 and BIM-23197 may prove to be superior to BIM-23014 for the treatment of acromegaly and some types of cancer."

Related Drugs and Biologics

1.	lanreotide (Somatuline)
2.	Cytostatic Agents
3.	Protein Tyrosine Phosphatases
4.	Somatostatin (Somatotropin Release-Inhibiting Factor)
5.	BIM 23268
6.	BIM 23197
7.	somatostatin receptor type 1
8.	somatostatin receptor 2